

Macon and Joan Brock Virginia Health Sciences at Old Dominion University
EASTERN VIRGINIA MEDICAL SCHOOL
Institutional Biosafety Committee
Minutes of July 14, 2025, Meeting

Members Present -

- | | |
|---|---|
| <input checked="" type="checkbox"/> Aurora Kerscher, Ph.D., <i>Co-Chair</i> | <input type="checkbox"/> Courtney Kerr, <i>Environmental Health & Safety</i> |
| <input checked="" type="checkbox"/> Elena Galkina, Ph.D., <i>Co-Chair</i> | <input checked="" type="checkbox"/> Chanda Hill, <i>Director, Research Compliance</i> <i>Joined ~12: 33</i> |
| <input checked="" type="checkbox"/> Bruce Finlay, BSO, <i>Environmental Health & Safety</i> | <input checked="" type="checkbox"/> Heather Singleton, M.S., <i>Ad Hoc, Occupational Health</i> |
| <input checked="" type="checkbox"/> Neelima Chandra, Ph.D., <i>Scientist</i> | <input type="checkbox"/> RaShae Y. O. Cook, M.S., <i>RLATG, CMAR Animal Expert</i> |
| <input checked="" type="checkbox"/> Kan Wang, Ph.D., <i>Scientist</i> <i>joined ~12:15</i> | <input type="checkbox"/> Daniel Sullivan, Ph.D., <i>Ad Hoc, IRB</i> |
| <input checked="" type="checkbox"/> Julius Nyalwidhe, Ph.D., <i>Scientist</i> | <input checked="" type="checkbox"/> David Mu, PhD. <i>Institutional Rep</i> |
| <input checked="" type="checkbox"/> Ming-Lei Guo, Ph.D., <i>Scientist</i> | |
| <input checked="" type="checkbox"/> Nancy Welch, M.D. <i>Consultant</i> | |
| <input checked="" type="checkbox"/> Yan Sanders, M.D., <i>Scientist</i> | |
| <input checked="" type="checkbox"/> Elizabeth Goodwyn, <i>Community Representative</i> | |
| <input type="checkbox"/> Jamie S. Heisig-Mitchell M.S., <i>Community Representative</i> | |

Office of Research Staff Present -

- Kimberly Powell, MS, IBC Administrator**

The Institutional Biosafety Committee (IBC) was held via Zoom on July 14, 2025. The IBC has 11 voting members and 7 of these are required to conduct formal business. A quorum was reached at 12:04 PM and the meeting was called to order by Dr. Galkina.

- I. **New Committee member introduction-** Ms. Elizabeth Goodwyn joined our IBC
- II. **Conflict of Interest -** Dr. Kerscher stated that she would have a COI with the Tang lab and Dr. Mu removed himself from the meeting while discussion of his lab bio-registration was going on. Dr. Chandra and Dr. Wang had to abstain from voting on Dr. Mu's review – as they are both listed on his Bio-registration.
- III. **Administrative Actions**
 - A. The minutes from the meeting on June 9, 2025, were reviewed by the IBC. Dr. Kerscher asked that the wording regarding notification of the PIs about the publicly posted IBC Roster be altered to show that it was Kim Powell who sent out the message. There was a motion to approve the amended minutes, and they were seconded. No motion against approval. The minutes were then approved unanimously.
- IV. **Registrations for Review -**
 - A. **Initial Reviews and 5-year Renewals**
 1. **Tang Lab – PI Dr. Amy Tang.** – The overall focus of this lab is the mechanisms and signaling pathways involved with cancer metastasis, and investigation of possible molecules to disrupt the metastatic process.
 - i. **Applicable NIH Guideline Sections**

(a) F-Appendix C-VII	(d) Section III-D-2
(b) F-Appendix C-VIII	(e) Section III-D-3
(c) Section III-D-1	(f) Section III-D-4-a

- (g) Section III-D-4-c-(2)
- (h) Section III-E
- (i) Section III-E-3
- (j) Section III-F-1
- (k) Section III-F-2

- (l) Section III-F-3
- (m) Section III-F-4
- (n) Section III-F-5
- (o) Section III-F-6
- (p) Section III-F-7

ii. **Projects - projects # 10109, 10110, 10111 and 10112** were reviewed

iii. **Source materials** - Human tissues and cells, murine tissues and cells, in vivo murine models, and arthropod models

iv. **Biosafety Level** - The presenter raised the issue that the ABSL should be 2 not 1, if any injection of human cell lines into model organisms is done.

v. **Viral vector registration – Lentivirus** – if Dr. Tang plans to do any further work involving Lentivirus, she should include a statement indicating that those involved have been properly trained and they have read and signed the *Lentiviral Safety Acknowledgment Form*. She should also include masks in the PPE when using lentivirus. Any work involving lentivirus or human cell injection should have clearly labeled containment, including in Comp Med facility. She should also indicate how long lentivirus particles would be shed.

vi. **IBC training** – Dr. Tang’s training is up to date, however, if any of her lab members are to do any shipping of samples, as her protocols indicate, they must complete the training module on shipping biological materials.

vii. **Biological waste disposal** - Dr. Tang should include statements about disposal of solid biological waste in the Human and Animal survey sections of her bio-registration.

viii. **IACUC** - Dr. Tang’s IACUC protocol is no longer active, so she must either obtain a new protocol and state that no work will be done until IACUC approval is obtained or remove the live animal work from her bio-registration.

ix. **Voting** – A motion was made to table until revisions are made –

- (a) Votes For (9)/ against (0)/ abstain (1)
- (b) Conflicts of Interest – Dr. Kerscher

B. Re-Review of Initial Reviews and 5-year Renewals

C. Annual Reviews with Significant Changes

1. **Mu Lab – PI Dr. David Mu.** – The focus of this lab is understanding the role of the cancer gene *thyroid transcription factor 1* (TTF-1) in lung cancer. The lab has also added a project formulating and evaluating a new drug for use in Gastrointestinal Acute Radiation Syndrome (GI-ARS).

i. Applicable NIH Guideline Sections

- (a) Section III-D-3
- (b) Section III-F-1
- (c) Section III-F-2
- (d) Section III-F-3
- (e) Section III-F-4
- (f) Section III-F-5
- (g) Section III-F-6
- (h) Section III-F-7

ii. **Project** - Identifier # 10209 (no changes), 10443 (no changes), and 10469 (new)

iii. Source materials - Human tissues and cells, murine tissues and cells

iv. IBC Vote –

(a) Votes For (8)/ against (0)/ abstain (2)

(b) Conflicts of interest -Dr. Wang & Dr. Chandra

D. Re-Review Annual Reviews with Significant Changes

(None)

E. Amendments to Registrations

(None)

F. Completed/Terminated Registrations

(None)

G. Final Approvals Granted

III. Old Business -

A. The requirement to publicly post Minutes was discussed. ODU would like to have both IBC minutes follow a similar format. We are waiting to hear from compliance regarding redaction. There was discussion of checking other institution's minutes to see what is being done. Dr. Mu will talk to UVA about this.

IV. New Business -

A.

Dr. Galkina adjourned the meeting at 12:48 PM.